In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
Harmony Biosciences Holdings Inc (NASDAQ: HRMY) closed the day trading at $27.04 up 1.05% from the previous closing price of $26.76. In other words, the price has increased by $1.05 from its previous closing price. On the day, 1.68 million shares were traded. HRMY stock price reached its highest trading level at $27.0624 during the session, while it also had its lowest trading level at $26.35.
Ratios:
For a better understanding of HRMY, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.75 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 6.01. For the most recent quarter (mrq), Quick Ratio is recorded 3.80 and its Current Ratio is at 3.84. In the meantime, Its Debt-to-Equity ratio is 0.27 whereas as Long-Term Debt/Eq ratio is at 0.20.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Truist on July 21, 2025, initiated with a Buy rating and assigned the stock a target price of $48.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 15 ’25 when Kapadia Sandip sold 21,573 shares for $36.50 per share. The transaction valued at 787,378 led to the insider holds 0 shares of the business.
SANDIP KAPADIA bought 21,573 shares of HRMY for $787,630 on Aug 15 ’25. On Jun 10 ’25, another insider, JEFFREY G DIERKS, who serves as the Former Officer of the company, bought 5,615 shares for $35.98 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HRMY now has a Market Capitalization of 1555681536 and an Enterprise Value of 1163780480. As of this moment, Harmony’s Price-to-Earnings (P/E) ratio for their current fiscal year is 8.72, and their Forward P/E ratio for the next fiscal year is 6.77. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.38. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.01 while its Price-to-Book (P/B) ratio in mrq is 2.01. Its current Enterprise Value per Revenue stands at 1.506 whereas that against EBITDA is 4.736.
Stock Price History:
The Beta on a monthly basis for HRMY is 0.80, which has changed by -0.3089701 over the last 52 weeks, in comparison to a change of 0.15101504 over the same period for the S&P500. Over the past 52 weeks, HRMY has reached a high of $41.61, while it has fallen to a 52-week low of $26.47. The 50-Day Moving Average of the stock is -22.89%, while the 200-Day Moving Average is calculated to be -20.92%.
Shares Statistics:
Over the past 3-months, HRMY traded about 700.31K shares per day on average, while over the past 10 days, HRMY traded about 1201660 shares per day. A total of 57.54M shares are outstanding, with a floating share count of 49.75M. Insiders hold about 13.53% of the company’s shares, while institutions hold 80.45% stake in the company. Shares short for HRMY as of 1756425600 were 4334580 with a Short Ratio of 6.07, compared to 1753920000 on 4224989. Therefore, it implies a Short% of Shares Outstanding of 4334580 and a Short% of Float of 16.49.
Earnings Estimates
Its stock is currently analyzed by 4.0 different market analysts. The consensus estimate for the next quarter is $1.05, with high estimates of $1.43 and low estimates of $0.76.
Analysts are recommending an EPS of between $4.68 and $3.5 for the fiscal current year, implying an average EPS of $3.96. EPS for the following year is $5.29, with 4.0 analysts recommending between $7.68 and $3.77.
Revenue Estimates
11 analysts predict $219.5M in revenue for the current quarter. It ranges from a high estimate of $224.8M to a low estimate of $212.69M. As of the current estimate, Harmony Biosciences Holdings Inc’s year-ago sales were $186.04MFor the next quarter, 11 analysts are estimating revenue of $235.72M. There is a high estimate of $247.4M for the next quarter, whereas the lowest estimate is $227.38M.
A total of 11 analysts have provided revenue estimates for HRMY’s current fiscal year. The highest revenue estimate was $854.95M, while the lowest revenue estimate was $825.3M, resulting in an average revenue estimate of $840.44M. In the same quarter a year ago, actual revenue was $714.73MBased on 11 analysts’ estimates, the company’s revenue will be $979.78M in the next fiscal year. The high estimate is $1.05B and the low estimate is $933.77M.
